Exchange: NASDAQ·Updated 07:58 PM EDT
SPRO logo

SPRO Spero Therapeutics Inc

$1.11
$0.02
(1.77%)
Today
Closed $1.11
$0.01
(0.90%)
After Hours
EarningsNov 12
Mkt Cap$64.64M
Vol316,552.00

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
43

Bearish Sentiment

How do you feel about SPRO?

Betchips
$SPRO $ACXP $ARMP took a position in these 3 for plague stocks. Could get interesting if these go wild. ChatGPT saying these are best under $5 .
7
n44
$SPRO Unusually high pre market volume and slightly higher bid price, maybe some good news coming.
4
DDel
$SPRO noticed freq promo gsk audio vaccine ads every time i'm in a walmart, along with some gsk promo posters at their pharmacy waiting area too. with next mo's exp u.s. release of tebi, and gsk's strong promo, i expect strong sales. added some more spro shs. i may reach out to u.s. gsk sales promo dept when tebi arrives in stock at local walmart rx.
4
DDel
$SPRO no doubt UK based global GSK wants UK & EU EMA appr of tebi too and under brilliant Tony Wood CSO is already well on their way to get this done asap in '27. GSK will save countless lives, needless hosp visits, make billions of sales globally with it, and imo believe they'll re-negot w spro to own it all, and spro sh value boldly takes off. long and
3
DDel
$SPRO GSK partner up green on a red market day. a good harbinger of things to come....in a bacterial drug resistance urgent world.... there would be no tebi w/o GSK global leader.
2
worldslargestpenguin
$SPRO historical statistics, from which quantiative strategies are derived, are bearish but the fundamental Truth here is bullish, Sjogren's is believed to be a $25B that's with a b billion program that its co-developer Innovent is advancing with $SPRO rights to the USA +$120M in net cash will be reported on 9/30/2026 earnings ~$2.10 per share and flip a number of buy programs/screens on to start accumulating $SPRO .....burn going forward will be less than $20M so next year in 9/30/2027 cash will be >$100M $1.76 per share .....and Sjogren's and the IGG4 program....so what's the probability that this doesn't work and they cut the program in 2028? Well hard to say but in 2028 we will still have $83M or $1.43 in cash.....and no major wall street sell-side coverage yet....
1

Advertisement|Remove ads.